Evidence map›Paper›PMID 27000464›Full record

ReviewThe oncologist2016

The Treatment of Colorectal Cancer During Pregnancy: Cytotoxic Chemotherapy and Targeted Therapy Challenges.

Jane E Rogers, Arvind Dasari, Cathy Eng

Open access · bronzeAbstract readReview
In one paragraph

Review in The oncologist, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 58 citations in OpenAlex.

  1. Review
  2. Colorectal Cancer Treatment During Pregnancy.Journal of the advanced practitioner in oncology · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Early-Onset Colorectal Cancer: From Genetic Discovery to Clinical Innovation.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2025
    Review
  11. Colon Cancer and Pregnancy.Clinics in colon and rectal surgery · 2025
    Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Observational
  17. Article
  18. Review
  19. Pregnancy and Gastric Cancer: A Narrative Review.Diagnostics (Basel, Switzerland) · 2023
    Review
  20. Early-onset colorectal cancer: A review of current knowledge.World journal of gastroenterology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jane E RogersPharmacy Clinical Programs, University of Texas MD Anderson Cancer Center, Houston, Texas, USA jerogers@mdanderson.org.
Arvind DasariDepartment of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Cathy EngDepartment of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
The University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelled: Cancer diagnosed during pregnancy has increased because of delayed child-bearing and the known occurrence of age-dependent malignancies. Cases of colorectal cancer (CRC) in pregnancy have recently been reported. With the expected rise in CRC diagnosed in young adults coupled with the current trend of delayed child-bearing, CRC during pregnancy is likely to increase. Treating pregnant women with CRC by using antineoplastics presents a dilemma because there are many unknowns to guide treatment decisions. We review the issues regarding the use of 10 CRC-approved agents in pregnancy. IMPLICATIONS FOR PRACTICE: Colorectal cancer (CRC) in pregnancy is likely to become more common because of the current population trend in delayed child-bearing and the increase in CRC incidence expected among young adults. Practitioners should become familiar with the challenges associated with systemic treatment of a pregnant patient with CRC. This review addresses concerns surrounding the 10 systemic agents approved for CRC to help provide treatment guidance when such a case arises.

Indexed as

Abnormalities, Drug-InducedAdultAngiogenesis InhibitorsAnimalsAntineoplastic AgentsColorectal NeoplasmsErbB ReceptorsFemaleFetusHumansMolecular Targeted TherapyPregnancyPregnancy Complications, NeoplasticYoung AdultAngiogenesis InhibitorsAntineoplastic AgentsErbB ReceptorsAntineoplasticsColorectal neoplasmsMonoclonal antibodiesPregnancy

Identifiers

PMID27000464
PMCPMC4861360
OpenAlexW2303528272

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.